drugset / Trial / NCT05823870

This Study is to Compare and Evaluate the Safety and Pharmacokinetic Characteristics (PK) After Administration of DW6014 and Each Component(Empagliflozin and Metformin) in Healthy Adult Volunteers in Fast Condition.

NCT05823870

Phase 1 Completed 32 enrolled Dong Wha Pharmaceutical Co. Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of DW6014 and each component in healthy adult volunteers in fast condition.

Timeline

Start
2023-02-24
Primary completion
2023-03-06
Completion
2023-03-20

Drugs

EvaluationDrugModalityDoseRoute
Subject DW6014 Unknown Oral
Subject Empagliflozin Small molecule Oral
Subject Metformin Small molecule Oral

Indications

No indication recorded.